What we do
Accelerate the mastery of biology to advance human health
10x Genomics is building tools for scientific discovery that reveal and address the true complexities of biology and disease. Through a combination of novel microfluidics, chemistry and bioinformatics, our award-winning Chromium System is enabling researchers around the world to more fully understand the fundamentals of biology at unprecedented resolution and scale.
Serge Saxonov co-founded 10x Genomics in 2012 and has served as the CEO since its inception. He defined vision and strategy, contributed to core inventions, and led the company through multiple phases of rapid growth. In 2016, he was honored as one of Goldman Sachs 100 Most Intriguing Entrepreneurs of the Year. Prior to 10x Genomics, Serge was VP of Applications at QuantaLife, where he was responsible for building content, driving new applications, and identifying key diagnostics opportunities for the core ddPCR technology. Before QuantaLife, Serge was Founding Architect and Director of R&D at 23andMe. There he defined the initial conception of the product, built many elements of the technology, and drove strategy and execution of R&D functions as the company scaled. Serge received a Ph.D. in biomedical informatics from Stanford University and an A.B. in applied mathematics from Harvard College.
Michelle K. Lee has served on the Board of Directors since May 2019. Ms. Lee also serves on the boards of alarm.com (NASDAQ: ALRM) and Nauto, Inc., including on their compensation and audit committees respectively. She was the Herman Phleger Visiting Professor of Law at Stanford University from 2017 until 2018, where she taught a class on disruptive technologies and their impact on existing laws, policies and regulations. From 2012 until 2017, Ms. Lee held various positions with the United States Patent and Trademark Office (USPTO), including most recently as the chief executive officer (Under Secretary of Commerce for Intellectual Property and Director) of the USPTO. Before her time in public service, Ms. Lee was deputy general counsel at Google Inc. and its first Head of Patents and Patent Strategy. Prior to Google, she was a partner at the law firm of Fenwick & West LLP. Ms. Lee earned a B.S. and an M.S. in Electrical Engineering and Computer Science from Massachusetts Institute of Technology and a J.D. from Stanford Law School. Ms. Lee also serves on the MIT Media Lab Advisory Committee.
Dr. Mammen’s mission is to work with the best research and development professionals in the world to make meaningful medicines that impact the lives of patients, their families and communities.
Prior to joining Janssen in June 2017, Dr. Mammen was Senior Vice President at Merck Research Laboratories, responsible for research in the areas of Cardiovascular, Metabolic and Renal Diseases, Oncology/Immuno-Oncology and Immunology. Jointly with his team, he initiated numerous new programs and progressed eight into early clinical development. He also nucleated a new discovery site in the San Francisco Bay Area.
Prior to Merck, Dr. Mammen led R&D at Theravance, a company he co-founded in 1997 based on his work at Harvard University. Under his leadership, the Theravance team of 200 scientists nominated 31 development candidates in 17 years, created three approved products (Breo®, Anoro®, Vibativ®), two additional assets that have successfully completed Phase 3 studies and a pipeline containing 11 further development-stage compounds in 2016. In 2014, he and the Theravance Leadership Team separated Theravance into two publicly traded companies: Innoviva (INVA) and Theravance Biopharma (TBPH).
Dr. Mammen has more than 150 peer-reviewed publications and patents and serves on various boards and advisory committees. He received his M.D. from Harvard Medical School/Massachusetts Institute of Technology (HST program) and his Ph.D. in Chemistry from Harvard University’s Department of Chemistry, working with George Whitesides. He received his BSc in Chemistry and Biochemistry from Dalhousie University in Halifax, Nova Scotia.
Sri Kosaraju has been a Board member of 10x Genomics since March 2019. He currently serves as Chief Financial Officer and Head of Strategy of Penumbra (NYSE: PEN), a global healthcare company focused on innovative therapies. Prior to joining Penumbra in 2015, Mr. Kosaraju had over 16 years of experience in investment banking. Mr. Kosaraju worked for J.P. Morgan Securities LLC (J.P. Morgan) from 1999 until 2015, where he held a variety of positions, most recently Managing Director of Equity Capital Markets, Head of Healthcare Equity Capital Markets and co-Head of Technology, Media, Telecom Equity Capital Markets. Mr. Kosaraju received a B.S in Mechanical Engineering from the Massachusetts Institute of Technology (MIT).
Join our expanding network of global distributors!
4 Miles St
Mulgrave, Victoria, 3170
1010, 165 Magokjungang-ro
Gangseo-gu, Seoul, 07788
Republic of Korea
Tel: +82 2 575 6227
Fax: +82 2 575 6228
Room 401, Building 10, Beijing Link
No. 6 Court JingShun East Street
Beijing 100015, China
Tel: +10 8440 9662-602
Fax: +10 8400 9672
4F., No. 17, Ln. 171, Sec. 2, Jiuzong Rd.,
Taipei City 11494, Taiwan
Tel: +886 2 2798 5885
Fax: +886 2 2798 6300
Kawakoshi Bldg. 3-9-2
Midori, Sumida-ku Tokyo 130-0021
Tel: +81 (0)3 5625 9711
Fax: +81 (0)3 3634 6333
Office 1610, Concord Tower
Dubai Media City
P.O. Box 500392
Dubai – UAE Tel: +971 4 375 2-44
Fax: +971 4 429 1376
Lyusinovskaya Street, 36/1
Tel: +7 (495) 215-02-22
Fax: +7 (495) 215-02-22
Akademijos str. 2
Tel: +370 5 2638748
Fax: +370 5 2638749
Tozkoparan Mah. Haldun Taner Sokak No:27 D:7
Alparslan İş Merkezi Merter-Güngören
Tel: 0212 481 3 444 pbx
Fax: 0212 481 5 444
Tel: +386 1 4273213
Fax: +386 1 4273191
Spectra building, 12th km
Thessalonikis- N.Moudanion str.,
Tel: +30 231 0322525
Fax: +30 231 0321912
Tel: +48 22 549 14 00
Fax: +48 22 549 14 01
Rua Dr. Álvaro de Castro, nº 77
Tel: + 351 217826030
Fax: + 351 217826039
Via Merendi 22 – 20010 Cornaredo (Mi)
Tel: +39 02 93991003